Dipyridamol shortage — NL supply status & alternatives

Dipyridamol

ATC B01AC07

🇦🇺 AUST R 17934 · Clinect Pty Ltd

In supply · Australia

In supply · 🇦🇺 Australia · short in🇳🇱 NL

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Controlled substance
Active ingredient (INN)	Dipyridamol
ATC level 5	B01AC07
ATC level 4	B01AC
Therapeutic category	Auto-created by CBG-MEB (Netherlands) scraper

Marketing-authorisation holders	ACCORD-UK LIMITED, ROSEMONT PHARMACEUTICALS LIMITED, STRIDES PHARMA UK LIMITED, CHELONIA HEALTHCARE LIMITED +7 more

Registrations on file	22

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

How long have past shortages lasted? from 1 resolved event

◷

~1 month

Historical pattern from resolved shortage records — not a prediction of this event.

Shortage status by regulator official notices

🇳🇴

Norway

NOMA · 11h ago

Resolved

🇳🇱

Netherlands

CBG-MEB · 13h ago

Medium

Verified timeline regulator events

🇳🇱 24 June 2026

medium reported

🇳🇱 15 June 2026

medium reported

🇳🇱 21 May 2026

medium reported

🇳🇴 17 Mar 2026

Shortage resolved

Sources official regulators

🇳🇴

NOMA

verified 11h ago

verify ↗

🇳🇱

CBG-MEB

verified 13h ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders22 registrations · 11 MA holders

Product	Strength	Form	Market	MA holder	Status
Dipyridamole Tablets Bp	25MG	tablet	🇬🇧 GB	ACCORD-UK LIMITED	Active
Dipyridamole Tablets Bp	100MG	tablet	🇬🇧 GB	ACCORD-UK LIMITED	Active
Dipyridamole	50MG	suspension	🇬🇧 GB	ROSEMONT PHARMACEUTICALS LIMITED	Active
Dipyridamole	200 MG	capsule	🇬🇧 GB	STRIDES PHARMA UK LIMITED	Active
Dipyridamole Bp	25MG	dipyridamole	🇬🇧 GB	CHELONIA HEALTHCARE LIMITED	Active
Dipyridamole Bp	100MG	dipyridamole	🇬🇧 GB	CHELONIA HEALTHCARE LIMITED	Active
Dipyridamole	25MG	tablet	🇬🇧 GB	GENETHICS EUROPE LIMITED	Active
Dipyridamole	100MG	tablet	🇬🇧 GB	GENETHICS EUROPE LIMITED	Active
Dipyridamole	25mg/1	tablet	🇺🇸 US	Amneal Pharmaceuticals of New York LLC	Active
Dipyridamole	50mg/1	tablet	🇺🇸 US	Amneal Pharmaceuticals of New York LLC	Active
Dipyridamole	75mg/1	tablet	🇺🇸 US	Amneal Pharmaceuticals of New York LLC	Active
PERSANTIN dipyridamole	10mg	—	🇦🇺 AU	Clinect Pty Ltd	Active
DIASPYRID SR Dipyridamole/Aspirin	200 mg	—	🇦🇺 AU	—	Active
DIPYRIDAMOLE/ASPIRIN SR GxP Dipyridamole/Aspirin	200 mg	—	🇦🇺 AU	—	Active
DIPYRAMOLE SR Dipyridamole/Aspirin	200 mg	—	🇦🇺 AU	—	Active

+7 more registrations on file

Mederti Drug Report

Generated 5 July 2026 · Australia market · 2 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.